Bioprospect buys into US diabetes company
Thursday, 17 March, 2005
Queensland company Bioprospect (ASX: BPO) has dipped deep into its pockets, paying US$530,000 for a third of private Seattle-based biotech Astrum Therapeutics, which is investigating compounds that arrest the destruction of insulin-secreting cells associated with type 1 diabetes.
"We like the diabetes market sector," said chief executive Selwyn Snell.
He said Astrum would screen compounds in Bioprospect's natural library for activity against diabetes and other conditions. "These guys are quite experienced in other sectors of pharmaceuticals and we would like them to have a look at some of our more interesting compounds in other areas which we're going to discuss with them."
At December 31, Bioprospect had cash at hand of AUD$554,572. Snell said the balance of funds for the acquisition had come from "services and products supplied plus R&D rebate money."
Russia insists there is "no plague case" following lab worker death
Russian health authorities say there is no evidence that pneumonic plague played a part in the...
Scientists 'reprogram' tumour-supporting immune cells
The approach, by an Australian team, uses lipid nanoparticles to target a type of immune cell...
Existing medicines could help treat deadly childhood dementia
Australian researchers have identified several existing TGA‑approved medicines that could help...
